BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24342949)

  • 41. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.
    Peterson LF; Boyapati A; Ahn EY; Biggs JR; Okumura AJ; Lo MC; Yan M; Zhang DE
    Blood; 2007 Aug; 110(3):799-805. PubMed ID: 17412887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.
    Da Silva N; Meyer-Monard S; Menot ML; Parrado A; Lebel A; Balitrand N; Fenaux P; Micléa JM; Rousselot P; Degos L; Dombret H; Chomienne C
    Hematol J; 2000; 1(5):316-28. PubMed ID: 11920209
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.
    Liu N; Song J; Xie Y; Wang XL; Rong B; Man N; Zhang MM; Zhang Q; Gao FF; Du MR; Zhang Y; Shen J; Xu CH; Hu CL; Wu JC; Liu P; Zhang YL; Xie YY; Liu P; Huang JY; Huang QH; Lan F; Shen S; Nimer SD; Chen Z; Chen SJ; Roeder RG; Wang L; Sun XJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):890-899. PubMed ID: 30593567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
    Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
    Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.
    Berg T; Fliegauf M; Burger J; Staege MS; Liu S; Martinez N; Heidenreich O; Burdach S; Haferlach T; Werner MH; Lübbert M
    Haematologica; 2008 Nov; 93(11):1728-33. PubMed ID: 18790797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
    Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
    Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
    Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
    Schnoeder TM; Schwarzer A; Jayavelu AK; Hsu CJ; Kirkpatrick J; Döhner K; Perner F; Eifert T; Huber N; Arreba-Tutusaus P; Dolnik A; Assi SA; Nafria M; Jiang L; Dai YT; Chen Z; Chen SJ; Kellaway SG; Ptasinska A; Ng ES; Stanley EG; Elefanty AG; Buschbeck M; Bierhoff H; Brodt S; Matziolis G; Fischer KD; Hochhaus A; Chen CW; Heidenreich O; Mann M; Lane SW; Bullinger L; Ori A; von Eyss B; Bonifer C; Heidel FH
    Blood; 2022 Feb; 139(7):1080-1097. PubMed ID: 34695195
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.
    Yuan Y; Zhou L; Miyamoto T; Iwasaki H; Harakawa N; Hetherington CJ; Burel SA; Lagasse E; Weissman IL; Akashi K; Zhang DE
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10398-403. PubMed ID: 11526243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Effective and specific control of aml1/eto gene expression in acute myeloid leukemia cells by lentivecior-based RNA-interference].
    Grinev VV; Posrednik DV; Heidenreich O
    Mol Biol (Mosk); 2011; 45(2):335-45. PubMed ID: 21634121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Transcriptome Study of Subtype M2 Acute Myeloblastic Leukemia.
    Wu AY; Yang HC; Lin CM; Wu BD; Qu QS; Zheng YH; Wei H; Mei XQ; Zeng ZH; Ma XD
    Cell Biochem Biophys; 2015 Jul; 72(3):653-6. PubMed ID: 27352183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polyphyllin I Inhibits Proliferation and Induces Apoptosis by Downregulating AML1-ETO and Suppressing C-KIT/Akt Signaling in t(8;21) Acute Myeloid Leukemia.
    Chai Y; Si Y; Xu J; Xiang Y; Zhao H; Si Y; Zhang T; Liu Y
    Chem Biodivers; 2018 Nov; 15(11):e1800314. PubMed ID: 30194712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
    Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
    J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.
    Zaidi SK; Dowdy CR; van Wijnen AJ; Lian JB; Raza A; Stein JL; Croce CM; Stein GS
    Cancer Res; 2009 Nov; 69(21):8249-55. PubMed ID: 19826043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
    Müller-Tidow C; Steffen B; Cauvet T; Tickenbrock L; Ji P; Diederichs S; Sargin B; Köhler G; Stelljes M; Puccetti E; Ruthardt M; deVos S; Hiebert SW; Koeffler HP; Berdel WE; Serve H
    Mol Cell Biol; 2004 Apr; 24(7):2890-904. PubMed ID: 15024077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
    Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
    Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD7+ near-tetraploid acute myeloblastic leukemia M2 with double t(8;21)(q22;q22) translocations and Aml1/ETO rearrangements detected by fluorescence in situ hybridization analysis.
    Yamamoto K; Nagata K; Kida A; Tsurukubo Y; Hamaguchi H
    Int J Hematol; 2001 Oct; 74(3):316-21. PubMed ID: 11721969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Translocation (8;17;15;21)(q22;q23;q15;q22) in acute myeloid leukemia (M2). a four-way variant of t(8;21).
    Vieira L; Oliveira V; Ambrósio AP; Marques B; Pereira AM; Hagemeijer A; Boavida MG
    Cancer Genet Cytogenet; 2001 Jul; 128(2):104-7. PubMed ID: 11463447
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.
    Duque-Afonso J; Solari L; Essig A; Berg T; Pahl HL; Lübbert M
    Br J Haematol; 2011 Jun; 153(5):612-22. PubMed ID: 21488857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
    Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
    Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.